Print

Sglt-2Inhibitors

Victor W Zhong, Juhaeri Juhaeri, Stephen R Cole, Christian M Shay, Carolyn A Chew-Graham, Penny Gordon-Larsen, Evangelos Kontopantelis, Elizabeth J Mayer-Davis

Type
Drug
ID
PH748
Version ID
1496
Data Sources
Valid event data range
01/04/1997 - 31/03/2014
Sex
Female, Male
Agreement Date
2017-10-23
Coding system
GPRD product codes
Tags /Collections
ClinicalCodes Repository Phenotype Library

Definition

Aims:

To determine association between HbA1C variability and hypoglycemia requiring hospitalization (HH) in adults with type 1 diabetes (T1D) and type 2 diabetes (T2D).

Methods:

Using nested case-control design in electronic health record data in England, one case with first or recurrent HH was matched to one control who had not experienced HH in incident T1D and T2D adults. HbA1C variability was determined by standard deviation of ≥3 HbA1C results. Conditional logistic models were applied to determine association of HbA1C variability with first and recurrent HH.

Results:

In T1D, every 1.0% increase in HbA1C variability was associated with 90% higher first HH risk (95% CI, 1.25–2.89) and 392% higher recurrent HH risk (95% CI, 1.17–20.61). In T2D, a 1.0% increase in HbA1C variability was associated with 556% higher first HH risk (95% CI, 3.88–11.08) and 573% higher recurrent HH risk (95% CI,1.59–28.51). In T2D for first HH, the association was the strongest in non-insulin non-sulfonylurea users (P b 0.0001); for recurrent HH, the association was stronger in insulin users than sulfonylurea users (P = 0.07). The HbA1C variability-HH association was stronger in more recent years in T2D (P ≤ 0.004).

Conclusions:

HbA1C variability is a strong predictor for HH in T1D and T2D.

Publications

  • Victor W Zhong, Juhaeri Juhaeri, Stephen R Cole, Christian M Shay, Carolyn A Chew-Graham, Penny Gordon-Larsen, Evangelos Kontopantelis, Elizabeth J Mayer-Davis, HbA1C variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: A nested case-control study. Journal of Diabetes and Its Complications, 32(2), 2017.

Clinical Code List

Rows: 8
Code Description Coding System (CPRD_product_code) Entity type Category
54182 Dapagliflozin 10mg tablets CPRD_product_code res50: SGLT-2 inhibitors drug
54203 Forxiga 10mg tablets (AstraZeneca UK Ltd) CPRD_product_code res50: SGLT-2 inhibitors drug
54265 Dapagliflozin 5mg tablets CPRD_product_code res50: SGLT-2 inhibitors drug
54480 Forxiga 5mg tablets (AstraZeneca UK Ltd) CPRD_product_code res50: SGLT-2 inhibitors drug
60012 Dapagliflozin 5mg / Metformin 1g tablets CPRD_product_code res50: SGLT-2 inhibitors drug
60211 Canagliflozin 100mg tablets CPRD_product_code res50: SGLT-2 inhibitors drug
60430 Invokana 100mg tablets (Janssen-Cilag Ltd) CPRD_product_code res50: SGLT-2 inhibitors drug
60643 Xigduo 5mg/1000mg tablets (AstraZeneca UK Ltd) CPRD_product_code res50: SGLT-2 inhibitors drug

API

To Export Phenotype Details:

Format API
XML site_root/api/v1/public/phenotypes/PH748/version/1496/detail/?format=xml
JSON site_root/api/v1/public/phenotypes/PH748/version/1496/detail/?format=json
R Package

# Download here

library(ConceptLibraryClient)


# Connect to API

client = connect_to_API(public=TRUE)


# Get details of phenotype

details = get_phenotype_detail_by_version('PH748', '1496', api_client=client)

To Export Phenotype Code List:

Format API
XML site_root/api/v1/public/phenotypes/PH748/version/1496/export/codes/?format=xml
JSON site_root/api/v1/public/phenotypes/PH748/version/1496/export/codes/?format=json
CSV site_root/phenotypes/PH748/version/1496/export/codes/
R Package

# Download here

library(ConceptLibraryClient)


# Connect to API

client = connect_to_API(public=TRUE)


# Get codelists of phenotype

codelists = get_phenotype_code_list('PH748', '1496', api_client=client)

Version History

Version
ID
Name Owner Publish date
1496 Sglt-2Inhibitors ieuan.scanlon 2021-10-06 currently shown

Export - export all codes into a csv file/JSON/XML for the current phenotype version.

Print - Print page.